Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 114

Sort by

Sort Order Select

Journal Articles

“Mast”ering drug discovery with iPSCs

Adrienne Dorrance

Blood (2021) 137 (15): 1993–1994.

https://doi.org/10.1182/blood.2020010456

Published: 2021

Journal Articles

How I treat relapsed or refractory AML

Susan DeWolf, Martin S. Tallman

Blood (2020) 136 (9): 1023–1032.

https://doi.org/10.1182/blood.2019001982

Published: 2020

Journal Articles

Characterization of a Genetically Engineered HUDEP2 Cell Line Harboring a Sickle Cell Disease Mutation As a Potential Research Tool for Preclinical Sickle Cell Disease Drug Discovery

Dipti Gupta, Sarah Sturtevant, BSc, Benjamin Vieira, BS, Yukio Nakamura, MD PhD, Sriram Krishnamoorthy, PhD, Melanie Demers, PhD

Blood (2019) 134 (Supplement_1): 3559.

https://doi.org/10.1182/blood-2019-127330

Published: 2019

Journal Articles

Altered Genomic and Epigenetic Profiling of Myeloma Bone Marrow Stromal Cells Identifies Targets for Current and Future Immunotherapeutic Approaches

Sophia Adamia, PhD, Daisuke Ogiya, MD PhD, Ivane Abiatari, MD, Sigitas J Verselis, PhD, Michael P. Chu, David M. Dorfman, MD PhD, Linda M. Pilarski, PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 3079.

https://doi.org/10.1182/blood-2019-131243

Published: 2019

Journal Articles

Patient-Derived Acute Myeloid Leukemia (AML) Ex Vivo platform for Evaluation of Novel Molecular Targeted Therapeutic Agents

Bhavna Verma, Nicolett Biel, Bruce Ruggeri, Amy Wesa

Blood (2019) 134 (Supplement_1): 5146.

https://doi.org/10.1182/blood-2019-126127

Published: 2019

Journal Articles

A Combination Strategy Targeting Enhancer Plasticity Exerts Synergistic Lethality Against Beti-Resistant Leukemia Cells

Lei Guo, PhD, Jia Li, PhD, Hongxiang Zeng, PhD, Anna Guzman, Tingting Li, MD, Minjung Lee, MS, Yubin Zhou, PhD, Clifford Stephan, Peter J.A Davies, Margaret Goodell, PhD, Deqiang Sun, PhD, Mark A. Dawson, PhD MBBS, Yun Huang, PhD

Blood (2019) 134 (Supplement_1): 5053.

https://doi.org/10.1182/blood-2019-130586

Published: 2019

Journal Articles

Targeting Bcl-2 Proteins in Myeloma

Martine Amiot, PhD

Blood (2019) 134 (Supplement_1): SCI-11.

https://doi.org/10.1182/blood-2019-121103

Published: 2019

Journal Articles

Role of Ubiquitin E3 Ligase UBR5 in B-Cell Development and Lymphoma

Tyler Gilbreath, B.S., Samantha Swenson, PhD, Shannon M. Buckley, PhD

Blood (2019) 134 (Supplement_1): 2794.

https://doi.org/10.1182/blood-2019-128747

Published: 2019

Journal Articles

Targeting AML: The Development of Two Functionally and Mechanistically Distinct Classes of Cereblon-Mediated Protein Homeostatic Modulators

Aparajita Hoskote Chourasia, PhD, Leah Fung, PhD, Brooke McElwee, BSc, Normand Richard, MSc, Imelda Lam, BSc, Eduardo Torres, MSc, Paul Erdman, MSc, Robert Sullivan, PhD, David Hecht, PhD, Kyle WH Chan, PhD, Frank Mercurio, PhD, David I Stirling, PhD

Blood (2019) 134 (Supplement_1): 3361.

https://doi.org/10.1182/blood-2019-131872

Published: 2019

Journal Articles

Therapeutic Applications of a Unique Calcium Channel Blocker to Target SF3B1 MDS

Sunisa Kongkiatkamon, Anand Tiwari, Vera Adema, PhD, Cassandra M Kerr, MS, Bartlomiej Przychodzen, Hassan Awada, Jibran Durrani, Yvonne Parker, Drew Adams, Yuriy Fedorov, Hetty E. Carraway, MD MBA, Chao-Yie Yang, Mikkael A. Sekeres, MD MS, Daniel J. Lindner, James G Phillips, PhD, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD

Blood (2019) 134 (Supplement_1): 881.

https://doi.org/10.1182/blood-2019-128671

Published: 2019

Journal Articles

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium

Blood (2018) 132 (Supplement 1): 261.

https://doi.org/10.1182/blood-2018-99-116948

Published: 2018

Journal Articles

Identification of Compounds That Target Acute Myeloid Leukemia Stem Cells Using a Scalable Next-Generation Screening Platform

Qiang Liu, PhD BSc, Amit Subedi, PhD, Changjiang Xu, Veronique Voisin, PhD, Gary D Bader, Steven M Chan, MD PhD, Jean C.Y. Wang, MD PhD

Blood (2018) 132 (Supplement 1): 259.

https://doi.org/10.1182/blood-2018-99-115323

Published: 2018

Journal Articles

Engineered Human Umbilical Cord Derived Erythroid Progenitor Cells (HUDEP2) with Sickle or β-Thalassemia Mutation: An in-Vitro System for Testing Pharmacological Induction of Fetal Hemoglobin

So Hyun Park, BS, Ciaran M Lee, PhD, Yankai Zhang, PhD, Alicia Chang, MD, Vivien A Sheehan, MD PhD, Gang Bao, PhD

Blood (2018) 132 (Supplement 1): 3478.

https://doi.org/10.1182/blood-2018-99-114241

Published: 2018

Journal Articles

SKY59: A Long-Lasting Engineered Anti-C5 Antibody for Subcutaneously Injectable Anti-Complement Therapy

Kenta Haraya, PhD, Zenjiro Sampei, PhD, Tatsuhiko Tachibana, PhD, Taku Fukuzawa, PhD, Siok Wan Gan, PhD, Meiri Shida-Kawazoe, PhD, Yuichiro Shimizu, PhD, Masaru Muraoka, PhD, Tomoyuki Igawa, PhD, Takehisa Kitazawa, DVM, Junichi Nezu, PhD

Blood (2018) 132 (Supplement 1): 3611.

https://doi.org/10.1182/blood-2018-99-110145

Published: 2018

Journal Articles

Single Cell Transcriptomics Maps the Embryonic Emergence of HSC and Identifies Intercellular Interactions Regulating HSC Genesis

Brandon Hadland, MD PhD, Barbara Varnum-Finney, Stacey Dozono, Dana Jackson, Shahin Rafii, MD, Irwin D. Bernstein, MD, Cole Trapnell, PhD

Blood (2018) 132 (Supplement 1): 5086.

https://doi.org/10.1182/blood-2018-99-118772

Published: 2018

Journal Articles

Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases

Yihong Guan, Anand D. Tiwari, PhD, Metis Hasipek, PhD, Dale Grabowski, BS, Yvonne Parker, Cassandra M. Hirsch, Amy C Graham, BS, MS, Yasunobu Nagata, Bartlomiej P. Przychodzen, Aziz Nazha, Daniel Lindner, MD PhD, Tomas Radivoyevitch, PhD, James G Phillips, PhD, Jaroslaw P. Maciejewski, Babal K. Jha

Blood (2018) 132 (Supplement 1): 4345.

https://doi.org/10.1182/blood-2018-99-117186

Published: 2018

Journal Articles

Predicting Drug Response and Novel Therapeutic Candidates Using Signatures of Molecular Alterations in Hematologic Malignancies

Guillaume Labilloy, MS, Eric O'Brien, BSc, Brett VanCauwenbergh, BSc, Luke Byerly, BSc, Mitali Basu, MSc, William Seibel, PhD, Erin H. Breese, MD PhD, John Peter Perentesis, MD, Mayur Sarangdhar, PhD

Blood (2018) 132 (Supplement 1): 2219.

https://doi.org/10.1182/blood-2018-99-119933

Published: 2018

Journal Articles

Development of Inhibitors of PIP4K2 As a Treatment for Patients with Hematologic Malignancies

Blood (2018) 132 (Supplement 1): 213.

https://doi.org/10.1182/blood-2018-99-118355

Published: 2018

Journal Articles

Integrated Genomic and Proteomic Analysis of Murine CLL-like Cells Reveals SF3B1 Mutation to Impact DNA Damage Response and BCR Signaling

Lili Wang, MDPhD, Shanye Yin, PhD, Aina zurita Martinez, Fara Faye Regis, BS, Angela Brooks, PhD, Sarah E. M. Herman, PhD, Elisa Ten Hacken, PhD, Esther Obeng, MD PhD, Dean Campagna, BS, Mark D. Fleming, MD DPhil, Benjamin L. Ebert, MDPhD, Adrian Wiestner, MD, Ignaty Leshchiner, PhD, Gad Getz, PhD, Ruben D. Carrasco, MD PhD, Catherine J. Wu, MD

Blood (2018) 132 (Supplement 1): 947.

https://doi.org/10.1182/blood-2018-99-117691

Published: 2018

Journal Articles

Targeting Distinct Promoter- and Enhancer-Driven Dependencies in Multiple Myeloma

Chandraditya Chakraborty, PhD, Mehmet Kemal Samur, PhD, Richard A. Young, PhD, Kenneth Anderson, MD, Charles Y Lin, PhD, Mariateresa Fulciniti, PhD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 3156.

https://doi.org/10.1182/blood-2018-99-112583

Published: 2018

NARROW

“Mast”ering drug discovery with iPSCs

How I treat relapsed or refractory AML

Characterization of a Genetically Engineered HUDEP2 Cell Line Harboring a Sickle Cell Disease Mutation As a Potential Research Tool for Preclinical Sickle Cell Disease Drug Discovery

Altered Genomic and Epigenetic Profiling of Myeloma Bone Marrow Stromal Cells Identifies Targets for Current and Future Immunotherapeutic Approaches

Patient-Derived Acute Myeloid Leukemia (AML) Ex Vivo platform for Evaluation of Novel Molecular Targeted Therapeutic Agents

A Combination Strategy Targeting Enhancer Plasticity Exerts Synergistic Lethality Against Beti-Resistant Leukemia Cells

Targeting Bcl-2 Proteins in Myeloma

Role of Ubiquitin E3 Ligase UBR5 in B-Cell Development and Lymphoma

Targeting AML: The Development of Two Functionally and Mechanistically Distinct Classes of Cereblon-Mediated Protein Homeostatic Modulators

Therapeutic Applications of a Unique Calcium Channel Blocker to Target SF3B1 MDS

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium

Identification of Compounds That Target Acute Myeloid Leukemia Stem Cells Using a Scalable Next-Generation Screening Platform

Engineered Human Umbilical Cord Derived Erythroid Progenitor Cells (HUDEP2) with Sickle or β-Thalassemia Mutation: An in-Vitro System for Testing Pharmacological Induction of Fetal Hemoglobin

SKY59: A Long-Lasting Engineered Anti-C5 Antibody for Subcutaneously Injectable Anti-Complement Therapy

Single Cell Transcriptomics Maps the Embryonic Emergence of HSC and Identifies Intercellular Interactions Regulating HSC Genesis

Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases

Predicting Drug Response and Novel Therapeutic Candidates Using Signatures of Molecular Alterations in Hematologic Malignancies

Development of Inhibitors of PIP4K2 As a Treatment for Patients with Hematologic Malignancies

Integrated Genomic and Proteomic Analysis of Murine CLL-like Cells Reveals SF3B1 Mutation to Impact DNA Damage Response and BCR Signaling

Targeting Distinct Promoter- and Enhancer-Driven Dependencies in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only